<DOC>
	<DOCNO>NCT02203838</DOCNO>
	<brief_summary>This Phase 3 , open label study administer RBP-7000 treatment patient schizophrenia . Study assess long-term safety tolerability RBP-7000 subcutaneous ( SC ) injection subject schizophrenia continue collect clinical outcome data RBP-7000 SC injection subject schizophrenia use Positive Negative Syndrome Scale ( PANSS ) Clinical Global Impression-Severity Illness ( CGI-S ) scale .</brief_summary>
	<brief_title>Long Term Study RBP 7000 Treatment Subjects With Schizophrenia</brief_title>
	<detailed_description>Patients screen must diagnose schizophrenia designate score base PANSS , confirm State , Assessability , Face , Ecological Rule ( SAFER ) interview . `` De novo '' patient patient already receive 3- 4-mg oral risperidone/day complete `` run-in '' `` conversion '' phase ( see ) assign receive RBP-7000 eligibility confirm . Patients complete double-blind , placebo-controlled , efficacy study RBP-7000 ( RB-US-09-0010 ) , conduct patient acute schizophrenia ( refer `` roll-over '' patient ) screen . All patient assign 120 mg dose RBP-7000 , subject one-time down-titration 90-mg RBP-7000 tolerability , investigator 's discretion . Patients receive 90-mg dose RBP-7000 exhibit worsen psychiatric symptom , confirm total PANSS score &gt; 70 20 % increase PANSS score previous assessment 120-mg dose level ( dose decrease 90 mg ) , receive one-time , up-titration back 120-mg RBP-7000 discretion investigator . De novo '' patient enter study patient participate stud RB-US-09-0010 categorize `` run-in '' patient . `` Run-in '' patient patient already receive oral risperidone ( antipsychotic medication allow study participation ) begin `` run-in-phase '' ; 14-day period titrate dose 3- 4-mg oral risperidone/day first injection RBP-7000 , clinically indicate . `` De novo '' `` conversion '' patient patient receive oral risperidone dose 3 4mg/day begin oral risperidone oral risperidone `` conversion '' phase seven-day period achieve oral risperidone dose level 3 4-mg first injection RBP-7000 , clinically indicate . `` Roll-over '' patient enter study patient complete 56 day double-blind treatment Study RB-US-09-0010 . These patient eligible enter current study provide continuation treatment clinically warrant , judge investigator , significant protocol deviation clinically relevant adverse event ( AEs ) would preclude inclusion study . Roll-over patient undergo complete screening process require either run-in conversion phase oral risperidone . On Visit 6 ( Day 1Â±2 day ) open-label study ( Day 57 Study RB-US-09-0010 ) , patient receive first dose ( 120 mg ) open label RBP-7000 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>`` De Novo '' Patients Diagnosis schizophrenia define Diagnostic Statistical Manual , Edition 4 , text revision ( DSMIVTR ) criteria Total PANSS score plus/minus70 time screen ( Visit 1 ) , confirm baseline ( Visit 6 ) Deemed 'valid ' State , Assessability , Face , Ecological Rule ( SAFER ) interview independent expert centralize rater Otherwise healthy basis physical examinatIon Provided write informed consent `` Rollover Patients Provided write consent participate study Be consider eligible enroll base End Study ( EOS ) ( Day 57 Study RBUS090010 ) assessments medical judgment investigator `` De Novo '' Patients Patients take daily oral risperidone dose plus/minus 6 mg/day Patients take Risperidone 9hydroxyrisperidone sustainedrelease formulation within 120 day study screen ( Visit 1 ) Patients receive sustainedrelease depot antipsychotic within 120 day screen ( Visit 1 ) Patients evidence history ( past six month prior screen ) significant hepatic disorder may either compromise patient safety interfere safety and/or outcome evaluation study drug , include : Acute chronic hepatitis , include limited hepatitis B C Total bilirubin great 1.5 x upper limit normal ( ULN ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2x ULN Patients history druginduced leucopenia Patients medical condition include , limited , history heart attack ( myocardial infarction ) brain injury ( traumatic injury loss consciousness and/or cerebrovascular accident ) , clinically significant low blood pressure arrhythmia interpret primary investigator ( PI ) medically qualified subinvestigator Patients epilepsy seizure disorder , Parkinson 's disease dementia `` Rollover '' Patients Patients require inpatient treatment set end Study RBUS090010 Patients unstable medical condition develop Study RBUS090010 Women childbearing potential positive pregnancy test screening ( Visit 1 ) , pregnant breastfeeding , seek pregnancy , fail use adequate contraceptive method study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophrenic</keyword>
	<keyword>Schizophrenias</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Long-acting Risperidone</keyword>
	<keyword>Atrigel</keyword>
	<keyword>Subcutaneous</keyword>
</DOC>